Cargando…

Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration

Cyadox (Cyx) is an antibacterial drug of the quinoxaline group that exerts markedly lower toxicity in animals, compared to its congeners. Here, the pharmacokinetics and metabolism of Cyx after oral (PO), intramuscular (IM), and intravenous (IV) routes of administration were studied to establish safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sattar, Adeel, Xie, Shuyu, Huang, Lingli, Iqbal, Zahid, Qu, Wei, Shabbir, Muhammad A., Pan, Yuanhu, Hussain, Hafiz I., Chen, Dongmei, Tao, Yanfei, Liu, Zhenli, Iqbal, Mujahid, Yuan, Zonghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971586/
https://www.ncbi.nlm.nih.gov/pubmed/27536243
http://dx.doi.org/10.3389/fphar.2016.00236
_version_ 1782446129225400320
author Sattar, Adeel
Xie, Shuyu
Huang, Lingli
Iqbal, Zahid
Qu, Wei
Shabbir, Muhammad A.
Pan, Yuanhu
Hussain, Hafiz I.
Chen, Dongmei
Tao, Yanfei
Liu, Zhenli
Iqbal, Mujahid
Yuan, Zonghui
author_facet Sattar, Adeel
Xie, Shuyu
Huang, Lingli
Iqbal, Zahid
Qu, Wei
Shabbir, Muhammad A.
Pan, Yuanhu
Hussain, Hafiz I.
Chen, Dongmei
Tao, Yanfei
Liu, Zhenli
Iqbal, Mujahid
Yuan, Zonghui
author_sort Sattar, Adeel
collection PubMed
description Cyadox (Cyx) is an antibacterial drug of the quinoxaline group that exerts markedly lower toxicity in animals, compared to its congeners. Here, the pharmacokinetics and metabolism of Cyx after oral (PO), intramuscular (IM), and intravenous (IV) routes of administration were studied to establish safety criteria for the clinical use of Cyx in animals. Six beagle dogs (3 males, 3 females) were administered Cyx through PO (40 mg kg(−1) b.w.), IM (10 mg kg(−1) b.w.), and IV (10 mg kg(−1) b.w.) routes with a washout period of 2 weeks in a crossover design. Highly sensitive high-performance liquid chromatography with ultraviolet detection (HPLC-UV) was employed for determination of Cyx and its main metabolites, 1, 4-bisdesoxycyadox (Cy1), cyadox-1-monoxide (Cy2), N-(quinoxaline-2-methyl)-cyanide acetyl hydrazine (Cy4), and quinoxaline-2-carboxylic acid (Cy6) in plasma, urine and feces of dogs. The oral bioavailability of Cyx was 4.75%, suggesting first-pass effect in dogs. The concentration vs. time profile in plasma after PO administration indicates that Cyx is rapidly dissociated into its metabolites and eliminated from plasma earlier, compared to its metabolites. The areas under the curve (AUC) of Cyx after PO, IM and IV administration were 1.22 h × μg mL(−1), 6.3 h × μg mL(−1), and 6.66 h × μg mL(−1), while mean resident times (MRT) were 7.32, 3.58 and 0.556 h, respectively. Total recovery of Cyx and its metabolites was >60% with each administration route. In feces, 48.83% drug was recovered after PO administration, while 18.15% and 17.11% after IM and IV injections, respectively, suggesting renal clearance as the major route of excretion with IM and IV administration and feces as the major route with PO delivery. Our comprehensive evaluation of Cyx has uncovered detailed information that should facilitate its judicious use in animals by improving understanding of its pharmacology.
format Online
Article
Text
id pubmed-4971586
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-49715862016-08-17 Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration Sattar, Adeel Xie, Shuyu Huang, Lingli Iqbal, Zahid Qu, Wei Shabbir, Muhammad A. Pan, Yuanhu Hussain, Hafiz I. Chen, Dongmei Tao, Yanfei Liu, Zhenli Iqbal, Mujahid Yuan, Zonghui Front Pharmacol Pharmacology Cyadox (Cyx) is an antibacterial drug of the quinoxaline group that exerts markedly lower toxicity in animals, compared to its congeners. Here, the pharmacokinetics and metabolism of Cyx after oral (PO), intramuscular (IM), and intravenous (IV) routes of administration were studied to establish safety criteria for the clinical use of Cyx in animals. Six beagle dogs (3 males, 3 females) were administered Cyx through PO (40 mg kg(−1) b.w.), IM (10 mg kg(−1) b.w.), and IV (10 mg kg(−1) b.w.) routes with a washout period of 2 weeks in a crossover design. Highly sensitive high-performance liquid chromatography with ultraviolet detection (HPLC-UV) was employed for determination of Cyx and its main metabolites, 1, 4-bisdesoxycyadox (Cy1), cyadox-1-monoxide (Cy2), N-(quinoxaline-2-methyl)-cyanide acetyl hydrazine (Cy4), and quinoxaline-2-carboxylic acid (Cy6) in plasma, urine and feces of dogs. The oral bioavailability of Cyx was 4.75%, suggesting first-pass effect in dogs. The concentration vs. time profile in plasma after PO administration indicates that Cyx is rapidly dissociated into its metabolites and eliminated from plasma earlier, compared to its metabolites. The areas under the curve (AUC) of Cyx after PO, IM and IV administration were 1.22 h × μg mL(−1), 6.3 h × μg mL(−1), and 6.66 h × μg mL(−1), while mean resident times (MRT) were 7.32, 3.58 and 0.556 h, respectively. Total recovery of Cyx and its metabolites was >60% with each administration route. In feces, 48.83% drug was recovered after PO administration, while 18.15% and 17.11% after IM and IV injections, respectively, suggesting renal clearance as the major route of excretion with IM and IV administration and feces as the major route with PO delivery. Our comprehensive evaluation of Cyx has uncovered detailed information that should facilitate its judicious use in animals by improving understanding of its pharmacology. Frontiers Media S.A. 2016-08-03 /pmc/articles/PMC4971586/ /pubmed/27536243 http://dx.doi.org/10.3389/fphar.2016.00236 Text en Copyright © 2016 Sattar, Xie, Huang, Iqbal, Qu, Shabbir, Pan, Hussain, Chen, Tao, Liu, Iqbal and Yuan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sattar, Adeel
Xie, Shuyu
Huang, Lingli
Iqbal, Zahid
Qu, Wei
Shabbir, Muhammad A.
Pan, Yuanhu
Hussain, Hafiz I.
Chen, Dongmei
Tao, Yanfei
Liu, Zhenli
Iqbal, Mujahid
Yuan, Zonghui
Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration
title Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration
title_full Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration
title_fullStr Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration
title_full_unstemmed Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration
title_short Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration
title_sort pharmacokinetics and metabolism of cyadox and its main metabolites in beagle dogs following oral, intramuscular, and intravenous administration
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971586/
https://www.ncbi.nlm.nih.gov/pubmed/27536243
http://dx.doi.org/10.3389/fphar.2016.00236
work_keys_str_mv AT sattaradeel pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT xieshuyu pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT huanglingli pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT iqbalzahid pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT quwei pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT shabbirmuhammada pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT panyuanhu pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT hussainhafizi pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT chendongmei pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT taoyanfei pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT liuzhenli pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT iqbalmujahid pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration
AT yuanzonghui pharmacokineticsandmetabolismofcyadoxanditsmainmetabolitesinbeagledogsfollowingoralintramuscularandintravenousadministration